NEJM @NEJM · 02 Sep 2026
In a phase 1–2 study of daraxonrasib, 54% of patients with RAS-mutant non–small-cell lung cancer had grade 3 or higher adverse events, mainly pneumonia, diarrhea, and rash; more than 30% of patients had a response. Full study results: https://t.co/4XFCWCgIwP https://t.co/BfBEAg7xxu
71 922Views
137Likes
37Reposts
0Replies
18Quotes
41Bookmarks
Is that a lot?
2.40×vs this author's median29 928 views is typical
80Percentile for this authorof 5 recent posts
1.08×vs 1M–10M median66 438 views is typical
6.96%Reachviews ÷ followers
0.27%Engagement rateof viewers reacted